Yuman Fong, MD on Safety of Gene-Edited Autologous NeoTCR-P1 #AACR2020

Yuman Fong, MD on Safety of Gene-Edited Autologous NeoTCR-P1 #AACR2020

Cancer-News

3 weeks
7 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.

Up Next Autoplay